JP2009518399A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009518399A5 JP2009518399A5 JP2008544384A JP2008544384A JP2009518399A5 JP 2009518399 A5 JP2009518399 A5 JP 2009518399A5 JP 2008544384 A JP2008544384 A JP 2008544384A JP 2008544384 A JP2008544384 A JP 2008544384A JP 2009518399 A5 JP2009518399 A5 JP 2009518399A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- acrylamide
- oxo
- pyrido
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 37
- -1 6-Acetylamino-5-hydroxy-pyridin-3-yl Chemical group 0.000 claims 30
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 4
- GDFIQPPSGCKCEK-UHFFFAOYSA-N prop-2-enamide;2,2,2-trifluoroacetic acid Chemical compound NC(=O)C=C.OC(=O)C(F)(F)F GDFIQPPSGCKCEK-UHFFFAOYSA-N 0.000 claims 4
- FJWSMXKFXFFEPV-UHFFFAOYSA-N prop-2-enamide;hydrochloride Chemical compound Cl.NC(=O)C=C FJWSMXKFXFFEPV-UHFFFAOYSA-N 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 1
- ONKQGXQUAJXPHR-AYJWMTRPSA-N (e)-3-(2,2-dimethyl-3-oxo-4h-pyrido[3,2-b][1,4]oxazin-7-yl)-n-[(1r)-1-(3-ethyl-1-benzofuran-2-yl)ethyl]-n-methylprop-2-enamide Chemical compound N1C(=O)C(C)(C)OC2=CC(/C=C/C(=O)N(C)[C@H](C)C3=C(C4=CC=CC=C4O3)CC)=CN=C21 ONKQGXQUAJXPHR-AYJWMTRPSA-N 0.000 claims 1
- OGPQDGUEPUIDQC-MDZDMXLPSA-N (e)-3-(3-amino-2,2-dimethylpyrido[3,2-b][1,4]oxazin-7-yl)-n-methyl-n-[(3-methyl-1-benzofuran-2-yl)methyl]prop-2-enamide Chemical compound N1C(=N)C(C)(C)OC2=CC(/C=C/C(=O)N(CC3=C(C4=CC=CC=C4O3)C)C)=CN=C21 OGPQDGUEPUIDQC-MDZDMXLPSA-N 0.000 claims 1
- ALWKZANDFLJGME-TYYBGVCCSA-N (e)-3-(4-oxo-1,2,3,5-tetrahydropyrido[2,3-b][1,4]diazepin-8-yl)prop-2-enoic acid;hydrochloride Chemical compound Cl.N1C(=O)CCNC2=CC(/C=C/C(=O)O)=CN=C21 ALWKZANDFLJGME-TYYBGVCCSA-N 0.000 claims 1
- BOBBZVXOLZDIBF-MDZDMXLPSA-N (e)-3-(5-hydroxy-6,6-dimethyl-7-oxo-5,8-dihydro-1,8-naphthyridin-3-yl)-n-methyl-n-[(3-methyl-1-benzofuran-2-yl)methyl]prop-2-enamide Chemical compound N1C(=O)C(C)(C)C(O)C2=CC(/C=C/C(=O)N(CC3=C(C4=CC=CC=C4O3)C)C)=CN=C21 BOBBZVXOLZDIBF-MDZDMXLPSA-N 0.000 claims 1
- ALUQZCDDMSOJCV-MDZDMXLPSA-N (e)-3-(5-hydroxy-7-oxo-6-propan-2-yl-8h-1,8-naphthyridin-3-yl)-n-methyl-n-[(3-methyl-1-benzofuran-2-yl)methyl]prop-2-enamide Chemical compound O1C2=CC=CC=C2C(C)=C1CN(C)C(=O)/C=C/C1=CN=C(NC(C(C(C)C)=C2O)=O)C2=C1 ALUQZCDDMSOJCV-MDZDMXLPSA-N 0.000 claims 1
- LHHOUFUKOIEGAK-RRABGKBLSA-N (e)-3-(6-acetamido-5-hydroxypyridin-3-yl)-n-[(3-methoxy-2-propoxyphenyl)methyl]-n-methylprop-2-enamide;hydrochloride Chemical compound Cl.C1=CC=C(OC)C(OCCC)=C1CN(C)C(=O)\C=C\C1=CN=C(NC(C)=O)C(O)=C1 LHHOUFUKOIEGAK-RRABGKBLSA-N 0.000 claims 1
- URZRGDYEMPNNET-OUKQBFOZSA-N (e)-3-(6-amino-5-phenylmethoxypyridin-3-yl)-n-methyl-n-[(3-methyl-1-benzofuran-2-yl)methyl]prop-2-enamide Chemical compound O1C2=CC=CC=C2C(C)=C1CN(C)C(=O)\C=C\C(C=1)=CN=C(N)C=1OCC1=CC=CC=C1 URZRGDYEMPNNET-OUKQBFOZSA-N 0.000 claims 1
- KMFSKNKVMPXULQ-IEZBTEQYSA-N (e)-3-(6-aminopyridin-3-yl)-n-[(1r)-1-(3-ethyl-1-benzofuran-2-yl)ethyl]-n-methylprop-2-enamide Chemical compound CN([C@H](C)C1=C(C2=CC=CC=C2O1)CC)C(=O)\C=C\C1=CC=C(N)N=C1 KMFSKNKVMPXULQ-IEZBTEQYSA-N 0.000 claims 1
- BFEJTYGIEAOXFN-ASTDGNLGSA-N (e)-3-[2,2-dimethyl-3-(methylamino)pyrido[3,2-b][1,4]oxazin-7-yl]-n-methyl-n-[(3-methyl-1-benzofuran-2-yl)methyl]prop-2-enamide;hydrochloride Chemical compound Cl.O1C2=CC=CC=C2C(C)=C1CN(C)C(=O)/C=C/C1=CN=C2N/C(=N/C)C(C)(C)OC2=C1 BFEJTYGIEAOXFN-ASTDGNLGSA-N 0.000 claims 1
- JLHKDYJQOZUARQ-ZHACJKMWSA-N (e)-3-[2,2-dimethyl-3-(methylamino)pyrido[3,2-b][1,4]oxazin-7-yl]-n-methyl-n-[(3-methyl-1-benzothiophen-2-yl)methyl]prop-2-enamide Chemical compound S1C2=CC=CC=C2C(C)=C1CN(C)C(=O)/C=C/C1=CN=C2N/C(=N/C)C(C)(C)OC2=C1 JLHKDYJQOZUARQ-ZHACJKMWSA-N 0.000 claims 1
- XWWNDAHDJKPNIN-ZHACJKMWSA-N (e)-3-[6-amino-5-(pyridin-2-ylmethoxy)pyridin-3-yl]-n-methyl-n-[(3-methyl-1-benzofuran-2-yl)methyl]prop-2-enamide Chemical compound O1C2=CC=CC=C2C(C)=C1CN(C)C(=O)\C=C\C(C=1)=CN=C(N)C=1OCC1=CC=CC=N1 XWWNDAHDJKPNIN-ZHACJKMWSA-N 0.000 claims 1
- AYRUXHHHKFHBCY-MDZDMXLPSA-N (e)-3-[6-amino-5-(pyridin-3-ylmethoxy)pyridin-3-yl]-n-methyl-n-[(3-methyl-1-benzofuran-2-yl)methyl]prop-2-enamide Chemical compound O1C2=CC=CC=C2C(C)=C1CN(C)C(=O)\C=C\C(C=1)=CN=C(N)C=1OCC1=CC=CN=C1 AYRUXHHHKFHBCY-MDZDMXLPSA-N 0.000 claims 1
- HSBHNIOHJODSGR-KPKJPENVSA-N (e)-n-(1,2-dihydroacenaphthylen-5-ylmethyl)-3-(5-hydroxy-7-oxo-6-propan-2-yl-8h-1,8-naphthyridin-3-yl)-n-methylprop-2-enamide Chemical compound C1CC2=CC=CC3=C2C1=CC=C3CN(C)C(=O)/C=C/C1=CN=C(NC(C(C(C)C)=C2O)=O)C2=C1 HSBHNIOHJODSGR-KPKJPENVSA-N 0.000 claims 1
- OAEIEFOPFGGAPK-CMDGGOBGSA-N (e)-n-[(1,3-dimethylindol-2-yl)methyl]-n-methyl-3-(2-oxo-1,3,4,5-tetrahydropyrido[2,3-b][1,4]diazepin-8-yl)prop-2-enamide Chemical compound N1CCC(=O)NC2=CC(/C=C/C(=O)N(CC=3N(C4=CC=CC=C4C=3C)C)C)=CN=C21 OAEIEFOPFGGAPK-CMDGGOBGSA-N 0.000 claims 1
- VIVGMQKXNPBMAH-CMDGGOBGSA-N (e)-n-[(1,3-dimethylindol-2-yl)methyl]-n-methyl-3-(3-oxo-4h-pyrido[3,2-b][1,4]oxazin-7-yl)prop-2-enamide Chemical compound N1C(=O)COC2=CC(/C=C/C(=O)N(CC=3N(C4=CC=CC=C4C=3C)C)C)=CN=C21 VIVGMQKXNPBMAH-CMDGGOBGSA-N 0.000 claims 1
- NAZCCBMUGDDHCB-CMDGGOBGSA-N (e)-n-[(2-ethoxy-3-methoxyphenyl)methyl]-3-(5-hydroxy-7-oxo-8h-1,8-naphthyridin-3-yl)-n-methylprop-2-enamide Chemical compound C1=CC=C(OC)C(OCC)=C1CN(C)C(=O)\C=C\C1=CN=C(NC(=O)C=C2O)C2=C1 NAZCCBMUGDDHCB-CMDGGOBGSA-N 0.000 claims 1
- IGGOOUBXAXVWAZ-VOTSOKGWSA-N (e)-n-[(3,6-dimethyl-1h-indol-5-yl)methyl]-n-methyl-3-(3-oxo-4h-pyrido[3,2-b][1,4]oxazin-2-yl)prop-2-enamide Chemical compound O1C2=CC=CN=C2NC(=O)C1/C=C/C(=O)N(C)CC(C(=C1)C)=CC2=C1NC=C2C IGGOOUBXAXVWAZ-VOTSOKGWSA-N 0.000 claims 1
- UTQGNSXZSCNDRK-BQYQJAHWSA-N (e)-n-[(3,7-dimethyl-1h-indol-2-yl)methyl]-n-methyl-3-(3-oxo-4h-pyrido[3,2-b][1,4]oxazin-7-yl)prop-2-enamide Chemical compound N1C(=O)COC2=CC(/C=C/C(=O)N(CC3=C(C4=CC=CC(C)=C4N3)C)C)=CN=C21 UTQGNSXZSCNDRK-BQYQJAHWSA-N 0.000 claims 1
- PUPHTZOSRKLTNQ-VOTSOKGWSA-N (e)-n-[(3-chloro-1-benzofuran-2-yl)methyl]-n-methyl-3-(3-oxo-4h-pyrido[3,2-b][1,4]oxazin-7-yl)prop-2-enamide Chemical compound N1C(=O)COC2=CC(/C=C/C(=O)N(CC3=C(C4=CC=CC=C4O3)Cl)C)=CN=C21 PUPHTZOSRKLTNQ-VOTSOKGWSA-N 0.000 claims 1
- FJRPPXSHTBVUNC-CMDGGOBGSA-N (e)-n-methyl-3-(3-oxo-4h-pyrido[3,2-b][1,4]oxazin-7-yl)-n-[(3-propan-2-yl-1-benzofuran-2-yl)methyl]prop-2-enamide Chemical compound O1C2=CC=CC=C2C(C(C)C)=C1CN(C)C(=O)\C=C\C1=CN=C(NC(=O)CO2)C2=C1 FJRPPXSHTBVUNC-CMDGGOBGSA-N 0.000 claims 1
- KRLIUPZXWVAMSP-KUCQQTCKSA-N (e)-n-methyl-n-[(1r)-1-(3-methyl-1-benzothiophen-2-yl)ethyl]-3-(7-oxo-6,8-dihydro-5h-1,8-naphthyridin-3-yl)prop-2-enamide Chemical compound S1C2=CC=CC=C2C(C)=C1[C@@H](C)N(C)C(=O)\C=C\C1=CN=C(NC(=O)CC2)C2=C1 KRLIUPZXWVAMSP-KUCQQTCKSA-N 0.000 claims 1
- FFCIEWRQYRCHLO-BQYQJAHWSA-N (e)-n-methyl-n-[(3-methyl-1-benzofuran-2-yl)methyl]-3-(2-oxo-1,5-dihydropyrido[2,3-e][1,4]oxazepin-7-yl)prop-2-enamide Chemical compound N1C(=O)COCC2=CC(/C=C/C(=O)N(CC3=C(C4=CC=CC=C4O3)C)C)=CN=C21 FFCIEWRQYRCHLO-BQYQJAHWSA-N 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 150000001924 cycloalkanes Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- JGKFRYAHUMFEPY-OAHLLOKOSA-N n-[(1r)-1-(3-ethyl-1-benzofuran-2-yl)ethyl]-n-methyl-3-(7-oxo-6,8-dihydro-5h-1,8-naphthyridin-3-yl)prop-2-enamide Chemical compound N1C(=O)CCC2=CC(C=CC(=O)N(C)[C@H](C)C3=C(C4=CC=CC=C4O3)CC)=CN=C21 JGKFRYAHUMFEPY-OAHLLOKOSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000001954 sterilising effect Effects 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- 0 Cc1c(*)c(C(**)=C(*)C2)c2c(*)c1* Chemical compound Cc1c(*)c(C(**)=C(*)C2)c2c(*)c1* 0.000 description 3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74251405P | 2005-12-05 | 2005-12-05 | |
| US75402405P | 2005-12-23 | 2005-12-23 | |
| PCT/US2006/045903 WO2007067416A2 (en) | 2005-12-05 | 2006-12-01 | Heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009518399A JP2009518399A (ja) | 2009-05-07 |
| JP2009518399A5 true JP2009518399A5 (enExample) | 2010-01-14 |
Family
ID=37945447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008544384A Pending JP2009518399A (ja) | 2005-12-05 | 2006-12-01 | Ｆａｂｉ阻害剤および抗菌剤としてのヘテロ環アクリルアミド化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20090156578A1 (enExample) |
| EP (1) | EP1973902A2 (enExample) |
| JP (1) | JP2009518399A (enExample) |
| KR (1) | KR20080075027A (enExample) |
| CA (1) | CA2632476A1 (enExample) |
| IL (1) | IL191987A0 (enExample) |
| WO (1) | WO2007067416A2 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60017180T2 (de) | 1999-10-08 | 2005-12-08 | Affinium Pharmaceuticals, Inc., Toronto | Fab i inhibitoren |
| CA2444597A1 (en) * | 2001-04-06 | 2002-10-06 | Affinium Pharmaceuticals, Inc. | Fab i inhibitors |
| AU2003298937A1 (en) * | 2002-12-06 | 2004-06-30 | Affinium Pharmaceuticals, Inc. | Heterocyclic compounds, methods of making them and their use in therapy |
| US8450307B2 (en) * | 2004-06-04 | 2013-05-28 | Affinium Pharmaceuticals, Inc. | Therapeutic agents, and methods of making and using the same |
| WO2008009122A1 (en) | 2006-07-20 | 2008-01-24 | Affinium Pharmaceuticals, Inc. | Acrylamide derivatives as fab i inhibitors |
| EP2125802A4 (en) | 2007-02-16 | 2014-08-20 | Debiopharm Int Sa | SALTS, PRODRUGS AND POLYMORPHES OF FAB I INHIBITORS |
| JP5270943B2 (ja) * | 2008-03-28 | 2013-08-21 | 大阪瓦斯株式会社 | フルオレン誘導体およびこのフルオレン誘導体を用いたアミノ基含有フルオレン誘導体の製造方法 |
| CN102470127A (zh) | 2009-08-19 | 2012-05-23 | 埃姆比特生物科学公司 | 联芳基化合物和其使用方法 |
| JP5816629B2 (ja) | 2009-11-18 | 2015-11-18 | ファブ ファーマ エスエーエス | 新規の複素環式アクリルアミド及び医薬としてのその使用 |
| WO2013042035A1 (en) * | 2011-09-19 | 2013-03-28 | Vitas Pharma Research Private Limited | Heterocyclic compounds as inhibitors of fatty acid biosynthesis for bacterial infections |
| DK2861608T3 (da) | 2012-06-19 | 2019-06-24 | Debiopharm Int Sa | Prodrug-derivater af (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamid |
| AU2017213628B2 (en) | 2016-02-05 | 2021-07-29 | Denali Therapeutics Inc. | Inhibitors of receptor-interacting protein kinase 1 |
| BR112018016721A2 (pt) | 2016-02-26 | 2018-12-26 | Debiopharm Int Sa | uso de di-hidrogeno fosfato de {6-[(e)-3-{metil[(3-metil-1-benfofuran-2-iol)metil]amino)-3-xopro-1-en-1-il]-2-oxo-3,4-di-hidro-1,8-naftiridin-1(2h)-il}metila e composição farmacêutica para tratamento de infecções bacterianas associadas ao pé diabético |
| WO2018107060A1 (en) | 2016-12-09 | 2018-06-14 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| US11691967B2 (en) | 2018-03-12 | 2023-07-04 | The Board Of Trustees Of The University Of Illinois | Antibiotics effective for gram-negative pathogens |
| PL3880675T3 (pl) * | 2018-11-12 | 2025-02-10 | Debiopharm International Sa | Związki antybiotykowe, sposoby ich wytwarzania, kompozycje farmaceutyczne zawierające te związki oraz ich zastosowanie |
| LT3923914T (lt) | 2019-02-14 | 2023-07-25 | Debiopharm International S.A. | Afabicino kompozicija, jos gamybos būdas |
| CA3139942A1 (en) | 2019-06-14 | 2020-12-17 | Justyna NOWAKOWSKA | Medicament and use thereof for treating bacterial infections involving biofilm |
| IL293980A (en) * | 2019-12-19 | 2022-08-01 | Debiopharm Int Sa | New compounds and their use |
| WO2022187329A1 (en) * | 2021-03-03 | 2022-09-09 | The Board Of Trustees Of The University Of Illinois | Fabi inhibitors for gram-negative pathogens |
| CA3223459A1 (en) | 2021-06-23 | 2022-12-29 | Vincent Gerusz | Novel compounds and their use |
| CN113861137B (zh) * | 2021-09-26 | 2023-08-15 | 重庆医科大学 | 酮与alpha氯代酮一步反应合成呋喃类化合物的方法 |
| EP4463229A1 (en) | 2022-01-12 | 2024-11-20 | Denali Therapeutics Inc. | Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide |
| WO2025073269A1 (zh) * | 2023-10-07 | 2025-04-10 | 广州白云山医药集团股份有限公司白云山制药总厂 | 一种FabI酶抑制剂及其应用 |
| WO2025078209A1 (en) | 2023-10-09 | 2025-04-17 | Debiopharm International S.A. | Antibiotic compounds for treating bacterial infections |
Family Cites Families (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3828068A (en) * | 1971-05-10 | 1974-08-06 | Tenneco Chem | ((substituted indazolyl)-n1-methyl)carbamates |
| US4154943A (en) * | 1977-12-29 | 1979-05-15 | University Of Vermont | Preparation of vincadifformine |
| FR2692575B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| US5416193A (en) * | 1993-04-30 | 1995-05-16 | Pfizer Inc. | Coupling reagent and method |
| US5614551A (en) * | 1994-01-24 | 1997-03-25 | The Johns Hopkins University | Inhibitors of fatty acid synthesis as antimicrobial agents |
| US6176842B1 (en) * | 1995-03-08 | 2001-01-23 | Ekos Corporation | Ultrasound assembly for use with light activated drugs |
| EP0824535B1 (en) * | 1995-05-11 | 2003-02-26 | Biochemie Gesellschaft M.B.H. | Antibacterial cephalosporins |
| US6057291A (en) * | 1995-06-02 | 2000-05-02 | University Of British Columbia | Antimicrobial cationic peptides |
| IL125214A0 (en) * | 1996-02-29 | 1999-03-12 | Fujisawa Pharmaceutical Co | Beta-lactam antibiotic-containing tablet and method for producing the same |
| US6367985B1 (en) * | 1996-03-12 | 2002-04-09 | Intellectual Property Company | Optical connector using large diameter alignment features |
| US6451816B1 (en) * | 1997-06-20 | 2002-09-17 | Klinge Pharma Gmbh | Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression |
| US6503881B2 (en) * | 1996-08-21 | 2003-01-07 | Micrologix Biotech Inc. | Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics |
| US6995254B1 (en) * | 1996-08-28 | 2006-02-07 | Affinium Pharmaceuticals, Inc. | Polynucleotide encoding the enoyl-acyl carrier protein reductase of Staphylococcus aureus, FAB I |
| CZ295199B6 (cs) * | 1996-09-20 | 2005-06-15 | Meiji Seika Kaisha Ltd. | Krystalický pivoxyl cefditoren a způsob jeho výroby |
| US6521408B1 (en) * | 1997-09-25 | 2003-02-18 | National Institute Of Agrobiological Sciences | Method for assessing a function of a gene |
| DE19652239A1 (de) * | 1996-12-16 | 1998-06-18 | Bayer Ag | Verwendung von 7-(2-Oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-chinolon- und -naphthyridoncarbonsäure-Derivaten zur Therapie von Helicobacter-pylori-Infektionen und den damit assoziierten gastroduodenalen Erkrankungen |
| DK0971735T3 (da) * | 1997-04-01 | 2008-07-07 | Borody Thomas J | Fremgangsmåder og præparater til behandling af inflammatorisk tarmsygdom |
| US6406880B1 (en) * | 1997-05-02 | 2002-06-18 | Integrated Research Technology, Llc | Betaines as adjuvants to susceptibility testing and antimicrobial therapy |
| US6184363B1 (en) * | 1997-06-13 | 2001-02-06 | Northwestern University | Inhibitors of β-lactamases and uses therefor |
| EP0995746A1 (en) * | 1997-06-23 | 2000-04-26 | Yoshitomi Pharmaceutical Industries, Ltd. | Prophylactic or therapeutic agent for diseases attributable to infection with helicobacters |
| AUPO758297A0 (en) * | 1997-06-27 | 1997-07-24 | Rowe, James Baber | Control of acidic gut syndrome |
| US6198000B1 (en) * | 1997-07-07 | 2001-03-06 | Pfizer Inc. | Intermediates useful in the synthesis of quinoline antibiotics |
| HN1998000106A (es) * | 1997-08-01 | 1999-01-08 | Pfizer Prod Inc | Composiciones parenterales de alatroflaxacino |
| US5932743A (en) * | 1997-08-21 | 1999-08-03 | American Home Products Corporation | Methods for the solid phase synthesis of substituted indole compounds |
| GB9717804D0 (en) * | 1997-08-22 | 1997-10-29 | Zeneca Ltd | Chemical compounds |
| US6432444B1 (en) * | 1997-10-31 | 2002-08-13 | New Horizons Diagnostics Corp | Use of bacterial phage associated lysing enzymes for treating dermatological infections |
| AU1558099A (en) * | 1997-10-31 | 1999-05-24 | Novartis Ag | Glyphosate resistant transgenic plants |
| SE9704404D0 (sv) * | 1997-11-28 | 1997-11-28 | Astra Ab | New compounds |
| DE19753298A1 (de) * | 1997-12-01 | 1999-06-02 | Basf Ag | Verfahren zur Herstellung von festen Dosierungsformen |
| US6184380B1 (en) * | 1999-01-25 | 2001-02-06 | Pfizer Inc. | Process for preparing naphthyridones and intermediates |
| PA8466701A1 (es) * | 1998-01-21 | 2000-09-29 | Pfizer Prod Inc | Comprimido de mesilato de trovafloxacino |
| US6204279B1 (en) * | 1998-06-03 | 2001-03-20 | Microcide Pharmaceuticals, Inc. | Peptidomimetic efflux pump inhibitors |
| BRPI9908182C1 (pt) * | 1998-02-27 | 2021-05-25 | Biora Ab | composições de proteína de matriz para cura de feridas |
| DE19820801A1 (de) * | 1998-05-09 | 1999-11-25 | Gruenenthal Gmbh | Orale Arzneiformen mit reproduzierbarer Wirkstofffreisetzung von Gatifloxacin oder pharmazeutisch verwendbaren Salzen oder Hydraten |
| DE19821039A1 (de) * | 1998-05-11 | 1999-11-18 | Bayer Ag | Verfahren zur Herstellung von (S,S)-Benzyl-2,8-diazabicyclo[4.3.0]nonan |
| US6399629B1 (en) * | 1998-06-01 | 2002-06-04 | Microcide Pharmaceuticals, Inc. | Efflux pump inhibitors |
| US6428579B1 (en) * | 1998-07-01 | 2002-08-06 | Brown University Research Foundation | Implantable prosthetic devices coated with bioactive molecules |
| US6423741B1 (en) * | 1998-07-10 | 2002-07-23 | Council Of Scientific And Industrial Research | Anti-microbial composition and method for producing the same |
| GB9815567D0 (en) * | 1998-07-18 | 1998-09-16 | Glaxo Group Ltd | Antiviral compound |
| US6514962B1 (en) * | 1998-08-04 | 2003-02-04 | Takeda Schering-Plough Animal Health K.K. | Stabilized preparations of β-lactam antibiotic |
| US6461607B1 (en) * | 1998-08-24 | 2002-10-08 | Ganeden Biotech, Inc. | Probiotic, lactic acid-producing bacteria and uses thereof |
| US6518487B1 (en) * | 1998-09-23 | 2003-02-11 | Pioneer Hi-Bred International, Inc. | Cyclin D polynucleotides, polypeptides and uses thereof |
| US6395746B1 (en) * | 1998-09-30 | 2002-05-28 | Alcon Manufacturing, Ltd. | Methods of treating ophthalmic, otic and nasal infections and attendant inflammation |
| US6509327B1 (en) * | 1998-09-30 | 2003-01-21 | Alcon Manufacturing, Ltd. | Compositions and methods for treating otic, ophthalmic and nasal infections |
| TW526202B (en) * | 1998-11-27 | 2003-04-01 | Shionogi & Amp Co | Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity |
| EP1154990B1 (en) * | 1999-02-18 | 2004-12-22 | The Regents Of The University Of California | Phthalamide-lanthanide complexes for use as luminescent markers |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| WO2000052035A1 (en) * | 1999-03-03 | 2000-09-08 | Princeton University | Bacterial transglycosylases: assays for monitoring the activity using lipid ii substrate analogs and methods for discovering new antibiotics |
| US6239113B1 (en) * | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
| CA2367173A1 (en) * | 1999-04-08 | 2000-10-12 | The General Hospital Corporation | Purposeful movement of human migratory cells away from an agent source |
| CO5180550A1 (es) * | 1999-04-19 | 2002-07-30 | Smithkline Beecham Corp | Inhibidores de fab i |
| US6290946B1 (en) * | 1999-05-13 | 2001-09-18 | Geltex Pharmaceuticals, Inc. | Anionic polymers as toxin binders and antibacterial agents |
| US6514535B2 (en) * | 1999-05-21 | 2003-02-04 | Noveon Ip Holdings Corp. | Bioadhesive hydrogels with functionalized degradable crosslinks |
| AR024077A1 (es) * | 1999-05-25 | 2002-09-04 | Smithkline Beecham Corp | Compuestos antibacterianos |
| AR024158A1 (es) * | 1999-06-01 | 2002-09-04 | Smithkline Beecham Corp | Compuestos antibacterianos |
| US6239141B1 (en) * | 1999-06-04 | 2001-05-29 | Pfizer Inc. | Trovafloxacin oral suspensions |
| CO5180605A1 (es) * | 1999-06-23 | 2002-07-30 | Smithkline Beecham Corp | Compuestos de indol |
| CA2282066C (en) * | 1999-06-29 | 2010-09-07 | Smithkline Beecham Corporation | Methods of use of quinolone compounds against atypical upper respiratory pathogenic bacteria |
| US6309663B1 (en) * | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| US6346391B1 (en) * | 1999-07-22 | 2002-02-12 | Trustees Of Tufts College | Methods of reducing microbial resistance to drugs |
| ATE270558T1 (de) * | 1999-08-26 | 2004-07-15 | Ganeden Biotech Inc | Verwendung von emu-öl als träger für fungizide, antibakterielle und antivirale arzneien |
| US6221859B1 (en) * | 1999-08-27 | 2001-04-24 | Merck & Co., Inc. | Carbapenem antibacterial compositions and methods of the treatment |
| US6174878B1 (en) * | 1999-08-31 | 2001-01-16 | Alcon Laboratories, Inc. | Topical use of kappa opioid agonists to treat otic pain |
| ES2282134T3 (es) * | 1999-09-11 | 2007-10-16 | THE PROCTER & GAMBLE COMPANY | Copolimeros de polioxialquileno que contienen vehiculos liquidos fluidos. |
| KR20010101030A (ko) * | 1999-09-17 | 2001-11-14 | 도리이 신이찌로 | 제약학적 항균 조성물 |
| US6730684B1 (en) * | 1999-10-08 | 2004-05-04 | Affinium Pharmaceuticals, Inc. | Fab I inhibitors |
| US6762201B1 (en) * | 1999-10-08 | 2004-07-13 | Affinium Pharmaceuticals, Inc. | Fab I inhibitors |
| DE60017180T2 (de) * | 1999-10-08 | 2005-12-08 | Affinium Pharmaceuticals, Inc., Toronto | Fab i inhibitoren |
| CA2323008C (en) * | 1999-10-11 | 2005-07-12 | Pfizer Inc. | Pharmaceutically active compounds |
| DE60014143T2 (de) * | 1999-10-19 | 2006-03-02 | Sato Pharmaceutical Co., Ltd. | Antimikrobielle 4-oxochinolizine mit 2-pyridongerüsten als teilstruktur |
| EP1666028B1 (en) * | 1999-10-29 | 2010-03-24 | Novartis AG | Dry powder compositions having improved dispersivity |
| US6531291B1 (en) * | 1999-11-10 | 2003-03-11 | The Trustees Of Columbia University In The City Of New York | Antimicrobial activity of gemfibrozil and related compounds and derivatives and metabolites thereof |
| US6514986B2 (en) * | 2000-11-22 | 2003-02-04 | Wockhardt Limited | Chiral fluoroquinolone arginine salt forms |
| US6372752B1 (en) * | 2000-02-07 | 2002-04-16 | Genzyme Corporation | Inha inhibitors and methods of use thereof |
| US6514541B2 (en) * | 2000-03-28 | 2003-02-04 | Council Of Scientific And Industrial Research | Formulation comprising thymol useful in the treatment of drug resistant bacterial infections |
| EP1280753A1 (en) * | 2000-04-21 | 2003-02-05 | Rhodia/Chirex, Inc. | Process for preparation of r-1-(aryloxy)propan-2-ol |
| US6503953B2 (en) * | 2000-07-26 | 2003-01-07 | Atopic Pty Ltd. | Methods for treating atopic disorders |
| US6288239B1 (en) * | 2000-09-19 | 2001-09-11 | Board Of Trustees Operating Michigan State University | 5-trityloxymethyl-oxazolidinones and process for the preparation thereof |
| US7048926B2 (en) * | 2000-10-06 | 2006-05-23 | Affinium Pharmaceuticals, Inc. | Methods of agonizing and antagonizing FabK |
| US6388070B1 (en) * | 2001-01-05 | 2002-05-14 | Orchid Chemicals & Pharmaceuticals Ltd. | Thioester derivatives of thiazolyl acetic acid and their use in the preparation of cephalosporin compounds |
| CA2444597A1 (en) * | 2001-04-06 | 2002-10-06 | Affinium Pharmaceuticals, Inc. | Fab i inhibitors |
| US6503906B1 (en) * | 2002-02-21 | 2003-01-07 | Ren-Jin Lee | Method for optimizing ciprofloxacin treatment of anthrax-exposed patients according to the patient's characteristics |
| AU2003298937A1 (en) * | 2002-12-06 | 2004-06-30 | Affinium Pharmaceuticals, Inc. | Heterocyclic compounds, methods of making them and their use in therapy |
| CA2519429C (en) * | 2003-03-17 | 2013-08-06 | Affinium Pharmaceuticals, Inc. | Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics |
| EP2125802A4 (en) * | 2007-02-16 | 2014-08-20 | Debiopharm Int Sa | SALTS, PRODRUGS AND POLYMORPHES OF FAB I INHIBITORS |
| AU2015314240A1 (en) * | 2014-09-10 | 2017-02-09 | AbbVie Deutschland GmbH & Co. KG | RGMa fragment based diagnostic assay |
-
2006
- 2006-12-01 EP EP06844684A patent/EP1973902A2/en not_active Withdrawn
- 2006-12-01 WO PCT/US2006/045903 patent/WO2007067416A2/en not_active Ceased
- 2006-12-01 JP JP2008544384A patent/JP2009518399A/ja active Pending
- 2006-12-01 KR KR1020087016424A patent/KR20080075027A/ko not_active Ceased
- 2006-12-01 US US12/095,977 patent/US20090156578A1/en not_active Abandoned
- 2006-12-01 CA CA002632476A patent/CA2632476A1/en not_active Abandoned
-
2008
- 2008-06-05 IL IL191987A patent/IL191987A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009518399A5 (enExample) | ||
| US12269825B2 (en) | Organic compounds | |
| AU2020202386C1 (en) | Novel methods | |
| AU2019236860B2 (en) | Organic compounds | |
| AU2017238842B2 (en) | Organic compounds | |
| US9745300B2 (en) | Organic compounds | |
| US9371324B2 (en) | Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders | |
| WO2017165755A1 (en) | Organic compounds | |
| HK40042185A (en) | Organic compounds |